Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
November 25, 2024 07:30 ET
|
Cassava Sciences, Inc.
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in the ReThink-ALZ Phase 3 study Simufilam...
Cassava Sciences to Hold Corporate Update on November 25th
November 24, 2024 20:01 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today...
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
November 18, 2024 08:30 ET
|
Cassava Sciences, Inc.
Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava’s commercial readiness strategy as the...
Cassava Sciences Reports Q3 2024 Financial and Operating Results
November 07, 2024 07:55 ET
|
Cassava Sciences, Inc.
Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026 ...
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
October 31, 2024 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a...
Cassava Sciences Resolves SEC Investigation
September 26, 2024 18:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
September 24, 2024 08:30 ET
|
Cassava Sciences, Inc.
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended Both Phase 3 Trials...
Cassava Sciences Names Rick Barry as Chief Executive Officer
September 09, 2024 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it has concluded its search for a...
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
September 03, 2024 08:31 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been...
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
August 08, 2024 08:00 ET
|
Cassava Sciences, Inc.
$207.3 Million in Cash and Cash Equivalents at June 30, 2024.Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for...